Table 1 Demographic data of participants*
|  | Healthy controls n = 11 | Mild asthma n = 13 | p-value |
|---|---|---|---|
Female, n (%) | 10 (91) | 6 (46) | 0.02 |
Age, years (range) | 21 (19–31) | 22 (19–29) | NS |
Oral anticonceptive use, n (%) | 4 (36) | 3 (23) | NS |
PC20 (mg/ml), geometric mean (95% CI) | >16 | 2.41 (1.29-4.48) | <0.001 |
FENO (ppb), mean (SD) | 23.3 (12.9) | 70.0 (36.8) | <0.05 |
FEV1 % pred. (range) | 102 (90–121) | 101 (80–123) | NS |
pbFEV1, % pred. (range) | 107 (98–127) | 104 (83–129) | NS |
PCR-positive for RV16 on day 6, n (%) | 9 (81) | 11 (85) | NS |
PCR-positive for RV16 on day 6 in BALf, n (%) | 3 (27) | 7 (54) | NS |
RV16 neutralization on day 42, n (%) | 9 (81) | 11 (85) | NS |